Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Return on Equity (2019 - 2025)

Cyclerion Therapeutics has reported Return on Equity over the past 7 years, most recently at 0.46% for Q3 2025.

  • Quarterly results put Return on Equity at 0.46% for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was 0.46% (changed N/A YoY), and the annual figure for FY2023 was 0.67%, up 155.0%.
  • Return on Equity for Q3 2025 was 0.46% at Cyclerion Therapeutics, down from 0.36% in the prior quarter.
  • Over the last five years, Return on Equity for CYCN hit a ceiling of 1.44% in Q2 2024 and a floor of 3.64% in Q1 2023.
  • Median Return on Equity over the past 5 years was 1.06% (2021), compared with a mean of 0.99%.
  • Biggest five-year swings in Return on Equity: crashed -236bps in 2023 and later soared 477bps in 2024.
  • Cyclerion Therapeutics' Return on Equity stood at 1.06% in 2021, then tumbled by -149bps to 2.62% in 2022, then soared by 123bps to 0.61% in 2023, then soared by 137bps to 1.44% in 2024, then tumbled by -132bps to 0.46% in 2025.
  • The last three reported values for Return on Equity were 0.46% (Q3 2025), 0.36% (Q2 2025), and 0.17% (Q1 2025) per Business Quant data.